EVP Chief Legal Officer McAvoy buys 1,113 shares of TEVA at $18.86; holdings rise to 13,027 shares (+9.3%).
David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical, purchased 1,113 shares at $18.86 on 2025-09-05, increasing his holdings by 9.3% to 13,027 shares for a total value of $20,988.06. The purchase occurred near the low end of the 52-week range ($12.82–$22.77), with the current price at $19.68 representing a 20.2% gain over the preceding 30 days and a 13.6% gain over 90 days. While the company reported positive quarterly net income of $282,000,000.00 on revenue of $4,176,000,000.00, it was unprofitable over the full fiscal year and has grown annual revenue by only 4.4%. An open-market purchase by a senior legal officer merits monitoring, but the modest transaction size ($21.0K), recent stock momentum (+20.2% in 30 days), and full-year profitability challenges provide limited directional clarity on forward company prospects.